Research and development (R&D) expenses: R&D expenses were $95.4 million and $81.8 million for the quarters ended December 31, 2025 and 2024, respectively. R&D expenses were $398.3 million and $281.4 ...

Shares of Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company, tumbled 30.7% on two key announcements. The company announced that some of its senior executives have stepped down from ...

Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -- Oral ...

A wave of fresh Buy calls after Dyne Therapeutics (DYN) updated data on its neuromuscular programs has put the stock back on traders radar, with analysts zeroing in on functionality, efficacy, and ...

A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be ...

Shares of Dyne Therapeutics (NASDAQ:DYN) dropped ~21% in the premarket on Tuesday after the company indicated a delay in filing for U.S. approval of DYNE-101, an experimental therapy for a rare muscle ...

The Dyne Therapeutics (DYN) stock price has jumped more than 8% premarket after it announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic ...

In a recent financial move, Jonathan McNeill, the Chief Business Officer of Dyne Therapeutics, Inc. (NASDAQ:DYNE), has sold a significant portion of his company stock. The transactions, which took ...

DYNE-251 received FDA breakthrough therapy designation for DMD, showing promising clinical evidence of improvement over existing therapies. The DELIVER trial demonstrated sustained functional ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months. Wall Street analysts have a consensus Strong Buy rating on ...